First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting.

Saved in:

Bibliographic Details
Title:	First-in-human imaging with ⁸⁹Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting.
Authors:	Pandit-Taskar, Neeta^1,2,3 pandit-n@mskcc.org, Postow, Michael A.^4,5, Hellmann, Matthew D.^3,4,5, Harding, James J.^4,5, Barker, Christopher A.⁶, O’Donoghue, Joseph A.⁷, Ziolkowska, Martha¹, Ruan, Shutian^1,2, Lyashchenko, Serge K.^8,9, Tsai, Frank¹⁰, Farwell, Michael¹¹, Mitchell, Tara C.¹¹, Korn, Ron¹², Le, William¹³, Lewis, Jason S.^1,8,9, Weber, Wolfgang A.¹, Behera, Deepak¹³, Wilson, Ian¹³, Gordon, Michael¹⁰, Wu, Anna M.^13,14
Source:	Journal of Nuclear Medicine. Dec2019, Vol. 60 Issue 12, Preceding p1-1. 39p.
Database:	Engineering Source

Description
ISSN:	01615505
DOI:	10.2967/jnumed.119.229781